Cantor Fitzgerald Comments on 89bio FY2025 Earnings

89bio, Inc. (NASDAQ:ETNB - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of 89bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($2.44) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $29.00 price target on the stock. The consensus estimate for 89bio's current full-year earnings is ($3.22) per share.

A number of other research firms have also recently commented on ETNB. Weiss Ratings reissued a "sell (d-)" rating on shares of 89bio in a research report on Saturday, January 18th. HC Wainwright reiterated a "buy" rating and set a $29.00 price objective on shares of 89bio in a report on Tuesday. Finally, Raymond James upgraded 89bio to a "strong-buy" rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

89bio Stock Up 2.5 %

Shares of NASDAQ:ETNB traded up $0.17 during trading on Thursday, reaching $6.92. The stock had a trading volume of 1,534,223 shares, compared to its average volume of 1,030,159. The firm's 50-day simple moving average is $7.80 and its 200 day simple moving average is $8.20. The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.09. 89bio has a one year low of $5.99 and a one year high of $16.63. The company has a market capitalization of $734.42 million, a P/E ratio of -2.38 and a beta of 1.14.

Hedge Funds Weigh In On 89bio

Institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in 89bio during the second quarter worth about $66,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of 89bio during the 4th quarter worth approximately $86,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of 89bio by 76.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,370 shares of the company's stock valued at $151,000 after purchasing an additional 8,810 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of 89bio in the 3rd quarter valued at $160,000. Finally, Quest Partners LLC boosted its holdings in 89bio by 172.1% during the third quarter. Quest Partners LLC now owns 22,074 shares of the company's stock worth $163,000 after buying an additional 13,961 shares in the last quarter.

Insider Activity

In other news, insider Quoc Le-Nguyen sold 10,963 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $6.49, for a total value of $71,149.87. Following the sale, the insider now directly owns 271,833 shares of the company's stock, valued at $1,764,196.17. This represents a 3.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rohan Palekar bought 5,000 shares of 89bio stock in a transaction that occurred on Friday, December 6th. The shares were acquired at an average cost of $7.89 per share, with a total value of $39,450.00. Following the acquisition, the chief executive officer now owns 471,236 shares of the company's stock, valued at $3,718,052.04. The trade was a 1.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 25,000 shares of company stock valued at $202,950 over the last ninety days. 2.80% of the stock is currently owned by insiders.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.